DPP1 inhibitor Brinsupri (brensocatib), given as a once-daily oral tablet, became the first therapy approved by the FDA for ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, ...

Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa) Secondary objectives me ...

For individuals with bronchiectasis, a history of chronic rhinosinusitis (CRS) is associated with culture positivity for ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...

(StatePoint) For Barb, who has been living with bronchiectasis for nearly 20 years, shortness of breath and an uncontrollable cough were a part of her daily life. She knew something was wrong because ...

Bulletin: ...FROST ADVISORY REMAINS IN EFFECT UNTIL 8 AM EDT TUESDAY... * WHAT...Temperatures as low as 33 will result in frost formation. * WHERE...A portion of ...

Bronchiectasis is a progressive inflammatory lung condition. Symptoms resemble those of more common respiratory conditions.